Statement of Changes in Beneficial Ownership (4)
March 03 2021 - 6:41PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Gross Paul Edward |
2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc.
[
CLVS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks |
(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/1/2021 |
(Street)
BOULDER, CO 80301
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/1/2021 | | M | | 469 | A | (1) | 43414 | D | |
Common Stock | 3/2/2021 | | S | | 207 (2) | D | $6.29 | 43207 | D | |
Common Stock | 3/1/2021 | | M | | 563 | A | (1) | 43770 | D | |
Common Stock | 3/2/2021 | | S | | 249 (2) | D | $6.29 | 43521 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Units | (1) | 3/1/2021 | | A | | 81000 | | (3) | (3) | Common Stock | 81000 | $0.00 | 81000 | D | |
Restricted Stock Units | (1) | 3/1/2021 | | M | | 469 | | (4) | (4) | Common Stock | 469 | $0.00 | 0 | D | |
Restricted Stock Units | (1) | 3/1/2021 | | M | | 563 | | (5) | (5) | Common Stock | 563 | $0.00 | 2250 | D | |
Explanation of Responses: |
(1) | Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
(2) | Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. |
(3) | The Restricted Stock Units shall vest as to 25% of the units on March 1, 2022, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. |
(4) | On March 27, 2017, the reporting person was granted 7,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
(5) | On March 1, 2018, the reporting person was granted 9,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
Remarks: Executive Vice President and General Counsel |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Gross Paul Edward C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301 |
|
| See Remarks |
|
Signatures
|
/s/ Paul Edward Gross | | 3/3/2021 |
**Signature of Reporting Person | Date |
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Sep 2023 to Sep 2024